Sterlite Technologies Ltd is likely to stay on investors’ radar after the company approved the opening of its Qualified Institutions Placement (QIP) issue on Jun 24, 2026. The company has fixed the floor price at ₹613.69 per equity share, while the final issue price will be determined in consultation with book running lead managers. The development assumes significance as QIP fundraising often signals a company’s capital raising strategy for expansion, deleveraging or future growth plans.
UTI Asset Management Company Ltd also announced key shareholder-related dates. The company has fixed Jul 14, 2026 as the record date for its proposed final dividend of ₹40 per equity share for FY26, subject to shareholder approval at its upcoming 23rd Annual General Meeting on Jul 21, 2026. The register of members and share transfer books will remain closed from Jul 15 to Jul 21, 2026 for dividend entitlement.
In another corporate development, Zydus Wellness Ltd said it has incorporated a step-down wholly owned subsidiary in Dubai, UAE, named Zydus Wellness Trading L.L.C. The new entity has been formed with a share capital of AED 300,000 and will operate in the food & nutrition, nutraceuticals and personal care segment. The company said the move is aimed at business expansion.
Among fundraising-related disclosures, Bhagyanagar India Ltd said its board will meet on Jun 30, 2026 to consider raising funds through multiple routes, including equity shares, warrants, convertible securities, QIP, rights issue or private placement.
On the shareholding front, Bacil Pharma Ltd disclosed that Manubhai Amrutlal Shah sold 3,94,893 shares, equivalent to a 2.75% stake, through open market transactions on Jun 23–24, 2026. Following the sale, his holding in the company stands at 10.02%. Separately, Deep Health AI India Ltd reported a change in its holding in Exxaro Tiles Ltd, while Gauri Aniruddha Mehta from the promoter group acquired 1,000 shares of Umiya Buildcon Ltd via the open market.
Hero MotoCorp Ltd also disclosed the approval of 52,056 RSUs and 75,000 PRSUs for employees under its stock-based compensation framework.
Disclaimer: This report is for informational purposes only and should not be construed as investment advice. Investors should conduct their own research or consult financial advisors before making investment decisions.
